Home
Company Info
- Management Team
- Bor-Wen Wu, PhD MBA
- John Bomalaski, MD
- Archie Prestayko, PhD
- W. Jenny Kung, PhD
- Wei He, PhD
- Jim Thomson, PhD
- Steve Wu
- Advisory Board
- Lloyd J. Old, MD
- Steven A. Curley, MD
- George Demetri, MD
- Robert C. Jackson, PhD
- Hsing-Jien Kung, MD PhD
- Jedd D. Wolchok, MD PhD
- Subsidiaries
- Polaris Pharmaceuticals
- TDW Pharmaceuticals
- DRX Pharmaceuticals
- DRX (Shanghai)
Pipeline
Collaborations
Literature
- Polaris & Collaborators
- ADI-PEG 20 (oncology)
- Uricase-PEG 20:
- TNF-PEG 20:
- CK2 inhibitor:
- ADI-PEG 20 (antiviral):
- Related Publications
- ADI general:
- ADI (oncology) renal cell carcinoma:
- ADI (oncology) combination therapy:
- TNF cancer treatment:
- CK2 inhibitor:
- Histidase cancer treatment:
Company News
Contact

Hyperuricemia

Hyperuricemia is the presence of abnormally high levels of uric acid in the blood. Elevated levels of uric acid can lead to a profound inflammatory response with resulting pain. In addition to pain, hyperuricemia can result in destructive gouty arthritis, with permanent damage to joints and connective tissue, and chronic renal disease. More recent data associate hyperuricemia with hypertension and vascular disease. Thus the deleterious effects of elevated uric acid are not limited to the joints and kidney.